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Sixty-four consecutive patients underwent renal homotrans-
plantation 10 1/6 to IH years ago, 46 from related and 18 
from nonrelated living donors. Thirty-six of these recipients 
were alive when this series was presented to the American 
Surgical Assoeation in 1965. Now, nine years later, 26 
(72%) of the 36 still survive, in 22 instances with function 
of their original grafts. The 10 who died in the interim 
tended to have subnormal renal function or graft failure. 
However, the actual causes of death included 2 or more 
examples each of myocardial infarction, hepatitis, or other 
systemic infections. The prognosis for achieving a one decade 
survival was not obviously related to HL-A tissue match. 
The best results were with related kidneys, within which 
subgroup 24 (52% ) of the original recipients are still alive. 
However, there was no particular category of consanguineous 
donor that had a marked superiority. Only 2 of 18 non-
related recipients are still alive. All 36 patients who were 
alive in 1965 had a biopsy of their renal homograft. Kidneys 
that were destined to function for a decade tended to have 
relatively minor histopathologic abnormalities. If serious 
glomerular lesions were found, the outlook for long graft 
survival was grave. Vascular lesions had a somewhat less 
serious import. Mononuclear cell infiltration, tubular atrophy, 
and interstitial fibrosis proved prognostically to be the least 
significant. Long-term followup of these early cases has 
shown the durability of chronic renal homografts, particularly 
if these are from related donors, and has demonstrated the 
very high degree of rehabilitation that could be achieved 
even in the early days of renal homotransplantation. 
A T THE MAY 1965 MEETING of the American Surgical Association a report24 was given on 64 consecutive 
renal homograft recipients treated at the Colorado Gen-
eral and the Denver Veterans Administration Hospitals. 
Thirty-six of these patients were still alive 13Jf-30 
months postoperatively. 
The climate between November 1962 and March 
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1964, when the series was compiled, had overtones 
of anxiety as well as excitement. Because the degree 
of success being achieved had not been anticipated by 
basic immunologists and for that matter was not yet 
generally appreciated by clinicians, expressions of criti-
cism and concern were common. 3 Lven those aware 
of the encouraging statistics of 1962-1963 conceded that 
the ultimate prognosis of the renal recipients still living 
was not predictable, since only very isolated examples 
of long-term survival had been recorded before this 
time. 8,11,13-15,22 
\Vith the passage of nine more years, followups ex-
ceeding a decade are now available for the 26 patients 
who still survive from the early Colorado series of 
1962-1964. Using the data of the American College 
of Surgeons Transplant Registry for a reference, these 
residual 26 patients account for about half of those in 
the world who were treated before March 1964 with 
renal homotransplantation and who remain alive today. 
Thus a description of their fate may servc as a bell-
weather for recipients treated in subsequent years who 
have been followed for briefer periods. 
Methods 
The 64 cases have been described elsewhere in 
great detail, including surgical techniques and manage-
ment.23 Transplantation was from related donors in 
46 instances, including 23 siblings, 20 parents, one 
aunt, one uncle, and one cousin. The other 18 donors 
were normal healthy volunteers. In six of the 64 cases, 
there was immediate or very early failure of an initial 
homograft which was promptly removed. A second 
kidney was provided 6-47 days after the original opera-
tion. In the foregoing description of organ source' and 
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in subsequent remarks only the second or definitive 
donor for these six recipients is considered. 
Typing procedures were not available when this 
series was compiled. After Case 23, the kind of red blood 
cell type incompatibility that can lead to hyperacute 
rejection~:l was avoidcd. Otherwise, the donor-recipicnt 
matching was not by any kind of immunologic guide-
lines. Parenthetically, one of our earliest recipients 
(LD 2) is still alive with perfect graft function cleven 
years and three months after transplantation from a B+ 
red cell type donor to an A + type recipient, a combi-
nation which would no longer be used. 
Between 1964 and 1970, retrospective HL-A typing 
was pcrformed by Terasaki of Los Angeles on surviving 
recipients and their donors.26 As a consequence, a state-
ment about the quality of HL-A match can be made for 
the last 36 survivors. This was cxprcssed as a letter histo-
compatibility grade. An A match indicated identity of 
the measured cIonor and rccipient HL-A antigcn groups. 
With a n match, no incompatibilities were present, 
but there were one or more examples of non-identity or 
else nonconformity of unclassified antigens. C and D-E 
matches were progressively less satisfactory with frank 
mismatches of one, two or more antigen groups. Because 
new HL-A groups were discovered and characterized 
throughout the period of analysis, the basis for grading 
was more complete and consequently more accurate at 
the end ofthc study than at the beginning. 
Immunosuppression was with the double drug combi-
nation of azathioprine and prednisone. Two regimens 
were uscd.23•25 In 45 cases azathioprine \vas started 
alone; prednisone was added in 43 of these 45 patients 
with the appearance of clinically obvious rejection. In 
the other 19 recipients hoth drugs were administered 
from the outset. Actinomycin C and local homograft 
irradiation werc employed irregularly. 
All 64 rccipients had splenectomy. The first eight, of 
whom fom are still alive (LD 1, 2, :3, 6) had prc-
transplantation thymectomy; patient LD 1 has under-
gone retransplantation. Nine additional patients had 
thymectomy 8Jf-17 months after transplantation in the 
hope of being able to reduce immunosuppression (LD 
13, 15, 22, 30, 40, 41, 47, 50, 54). Five of the latter nine 
recipients are still alive but two arc dcpendent upon 
rctransplanted kidneys and a third one is presently 
anephric. Although thymectomy may have a subtlc long-
term immunosuppressive effect in adult humans,2G it is 
no longer performed at our institution either before or 
after transplantation. 
Betwecn 21 and 26 months postoperative, 35 of the 
36 patients living in 1965 had open homograft biopsy; 
the thirty-sixth graft (LD 44) was retrieved hy homo-
graft nephrectomy after 60 months. In seven cases, it 
was possible to compare two-year biopsies with the 
same kidney retrieved OF~-T years later at autopsy or 
homograft nephrectomy. Invariably the same abnormali-
ties were present both times but were more advanced 
on thc later occasion. 
All the tissues were examined by light microscopy. 
Sections were cut at both 5 fl and 0.5 fL. The former 
were stained with hematoxylin and cos in, periodic acid 
Schiff (PAS), Weigert's for elastic countcrstained with 
hematoxylin and van Gieson, and methyl green pyronin. 
The 0.5 l" thick sections were stained with Azur 2. 
Electron microscopy was carried out on all of the 
specimens. The tissue from biopsies was primarily fixed 
in Palade's buffered osmium tetroxide and embedded 
in Epon 812. Autopsy material was fixed in buffered 
formalin and then post-fixed in osmium tetroxide. Ultra-
thin scctions were stained with lead citrate and exam-
ined in a Phillips 300 electron microscope. 
From 27 of the homografts, samples of tissue were 
frozen in liquid nitrogen and stored at -70 C until 
examined. Sections 4 .l" thick were cut in a cryostat and 
stained with fluorescein conjugatecl antisera. The fluores-
cent reagents used were antisera made in rabbits and 
goats to human IgG, IgM, fibrinogen, C'lq and ;nc/ f31A 
globulin. SpecifiCity of the antisera was confirmed before 
application to the tissue by immunoelcctrophoresis and 
double diffusion in agarose. Specificity of the fluores-
cence was established by blocking positive reactions 
with unconjugatedantisera, by absorption of the labelled 
antisera with specific antigens, and by the usc of an 
antihuman serum albumin control. 
Using light microscopic and ultrastructural analysis, 
the presence or absence of the following features was 
determined in the homografts: 1) subendothelial glomer-
ular capillary basement membranc thickening; 2) sub-
epithelial glomerular capillary basement membrane 
thickening; 3) increased cellularity of thc glomerular 
tufts; 4) increased amount of mesangial matrix; 5) 
tubular atrophy; 6) interstitial fibrosis; 7) mononuclear 
cell infiltration of the interstitium; 8) "hyaline" in the 
ateriolar walls; and 9) thickening of the intima of the 
interlobular arteries. In addition, the frozen tissues were 
used to determine deposits of IgG, IgM, complement 
or fibrinogen in the glomeruli. The lesions and deposits 
were graded in severity from 0 to 4. 
Eventually, the Glomerular Categories 1-4 werc com-
bined and averaged to reach a summary score of the 
magnitude of abnormalities (glomerular index); the 
immunofluorescence examinations were always roughly 
confirmatory of the morphologic scores. The grades for 
all nine microscopic categories were averaged for an 
overall "pathologic index." The ultimate fate of these 
kidneys was correlated with the various pathologic 
lesions. 
In 33 of the 36 cases, thc patients' own diseased kid-
neys were examIned and the findings werc ultimately 
compared to those in the homografts. These specimens 
were all studied by light microscopy and in a few 
instances by immunofluorescence and/or electron micros-
copy. 
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FIG. 1. The life survival curves of 64 patients treated by renal 
transplantation between the autumn of 1962 and March 1964. 
These cases were reported to the American Surgical Association in 
May 1965, at which time the life survival curves had evolved to 
the points indicated by the black arrow. Note that 72% of the sur-
vivors of 1965 are still alive 9 years later. The denominators in 
parentheses indicate the number of living recipients and the 
numerators indicate the original homografts that are still function-
ing. 
Results 
Survival 
Related Cases. By May 1965, 15 of the 46 related 
recipients had died, leaving a residual group of 31 
(Fig. 1). At the three-, five- and ten-year marks, the 
recipients remaining numbered 29, 28 and 24 respec-
tively. There are 24 or 52% of the original 46 who are 
still alive after 1M%-11~~ years. No one of the survivors 
is now on dialysis. Twenty-one of the 24 have function 
of their original grafts. The other three underwent re-
transplantation (Table 1) when their original kidneys 
failed after ,5% years (LD 1), 6 years (LD 41) and 
5 years (LD 50). Second grafts from the other parent 
have functioned satisfactorily for 6 years in Patient LD 1 
and 4% years in LD 50. The third patient (LD 41) 
has had four cadaveric retransplantations. The first three 
of these grafts underwent hyperacute, acute, or delayed 
rejection. The final kidney has been functioning satis-
factorily for 16 months. 
The survival in the consanguineous cases was not 
strikingly influenced by the nature of the relationship 
(Table 2). After parent-to-offspring transplantation, 14 
of 20 recipients (70%) were alive at the end of six 
montbs. By 10%-11 ~f years there were still 13 (65%) 
alive, although three of these have undergone retrans-
plantation. Also of interest was the fact that all of the 
three distantly related renal grafts (aunt, unclc, and 
cousin) were providing stable function more than a 
decade after their insertion (Table 2). The greatest 
attrition was of sibling recipients (Table 2), amongst 
whom a 61% one-year survival had eroded to 35% after 
a decade. 
Nonrelated Cases. By May 1965, only five of the 18 
nonrelated recipients were still alive (Fig. 1). In the 
intervening nine years, three more have died leaving 
only two. One of these two recipients who is now ten 
years, two months, probably has the longest continuously 
functioning unrelated homograft in the world. Thc sec-
ond surviving patient lost his unrelated graft after a 
little more than two years (LD 54). He underwent 
successful retransplantation with his mother's kidney 
in September 1966 (Table 1). After six years of essen-
tially normal function, he became mentally depressed 
and discontinued all immunosuppression. After five or 
six months the maternal kidney failed. He was returned 
to chronic hemodialysis and is awaiting a cadaver organ. 
Causes of Late Death. The ten patients who died 
between 1965 and 1974 included seven recipients of 
related grafts and three recipients of unrelated organs; 
five of them (LD 15, 18, 36, 47 and 48) had life-
sustaining although subnormal function of their original 
grafts from one-and-three-quarters to nine years post-
operatively (Table 3). The deaths of two of these five 
patients were caused by acute myocardial infarction 
(LD 18 and LD 48). A third patient who died almost 
nine years after transplantation (LD 15) had moderately 
severe chronic aggressive hepatitis which was first diag-
nosed eight years earlier; in addition, the immediate 
cause of death was acute hemorrhagic pancreatitis. The 
two other patients who died with functioning original 
kidneys (LD 36 and 47) had multiple infections 
(Table 3). 
One of the other five patients died after he was placed 
back on dialysis but before retransplantation could be 
considered (LD 45). He had a cardiac arrest just at 
the conclusion of a dialysis treatment. 
The other four patients had attempts at retransplanta-
tion which were followed by a variety of lethal compli-
cations (Table 3), including suicide, perforated sigmoid 
diverticulitis and bronchopneumonia. The longest sur-
TABLE 1. Four Patients Alil'e After One or ,tfore Late Retransplantations 
Present 
Total 
Date First Original Date Retransplant BUN eer BP Prednisone Survival 
LD Number Transplantation Donor Retransplantation( s) Donor mg% ml/min mml/Hg mg/day Years 
1 11/2 .. /62 l\Iother 5/21/68 Father 18 60 100/70 1 S 11.4 
41 11/23/63 ::\Iother 1/22/70 Cadavers 29 40 124/90* 25 10.4 
6/29/70 
2/27/71 
12/29/72 
50 1/25/64 Father 11/7/69 Mother 29 48 120/85 14 10.3 
54 2/24/64 Unrelated 9/26/66 Mother Anephric for 1 1/2 yrs. 0 10.2 
* Receiving reserpine and hydralazine. 
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TABLE 2. Influence of Consanguinity Upon Present Survival in 46 Related Cases, 101/6-11 1/2 Years Later 
1 Year 3 Years 5 Years Now 
Donor 
20 Parents 
23 Sibling-s 
3 Aunt, Uncle, or COllsin 
Patient 
14 
14 
3 
Graft 
14 
14 
3 
Patient 
14 
12 
3 
Graft 
14 
12 
3 
Patient Graft 
14 (70%) 14 (70%) 
11 (48%) 11 (48%) 
3 (100%) 3 (100%) 
Patient Graft 
13 (65%)* 10 (50%) 
8 (35%) 8 (35%) 
3 (100%) 3 (100%) 
* Retransp\;lntation was carried out after 5 1/2, 5 3/4, and 6 1/6 years. 
viving patient (LD 40) died of hepatic failure secondary 
to chronic aggressive hepatitis, Australia antigen posi-
tive, 18 months after successful cadaveric retransplanta-
tion and eight years, two months after the original 
transplantation. 
Renal Function, Blood Pressure and Immunosuppression 
The current renal functions of the four survivors who 
have undergone retransplantation is shown in Table 1. 
Table 4 contains the functions from 22 primary kidneys 
that have functioned for 10Ya to 11 y:! years. On the 
average, the function of the organs is superb. Only one 
of the original grafts is distinctly subnormal. 
The average daily doses of prednisone are small 
enough so that only one of the 26 patients (the most 
recent retransplant) has a Cushing's facies. There are 
no examples of steroid-induced diabetes. Most of the 
patients have had stable azathioprine doscs for years. 
Over the years, we have had a number of patients 
discontinue immunosuppressive treatment, usually be-
cause of indifference to the tedium of following a thera-
peutic schedule. One of the chronic survivors (LD 49) 
in this early series discontinued all medications about 
14 months ago without any untoward effect to date. 
Another recipient (LD 3), who also was brain-damaged 
from a stroke prior to transplantation, has become an 
alcoholic in the lUi years of survival. This patient who 
has ncver requircd prednisone probably discontinued 
has azathioprine in 1970 or 1971. 
Arterial hypertension is an almost universal finding 
in the immediate posttransplantation period and even 
for several years afterwards.26 With longer followup, 
only one of the 25 survivors who has renal function 
(and this the retransplant recipient of 16 months ago) 
has severe hypertension. Four other patients receive 
small daily doses of antihypertensives. The other re-
cipients require no antihypertensive therapy. 
The Influence of HL-A Match 
Among the 36 patients alive in May 1965, the quality 
of the HL-A match did not profoundly influence the 
durability of the homografts in the succeeding nine 
years (Tables 4, 5). 
The Incidence of Malignancy 
Neoplasia was not diagnosed in any of the 28 patients 
who died before May 1965, after survivals that had 
ranged from a few days to more than 13 months. Six 
( 17%) of the 36 recipients who remained alive at that 
time developed malignant lesions at some time during 
the ensuing nine years. These tumors all originated in 
the skin and were all successfully treated with conven-
tional means. The features of these carcinomas are 
summarized in Table 6. 
Rehabilitation 
The social and vocational rehabilitation amongst the 
26 present survivors has bcen very nearly complete. 
TABLE 3. Cause oj 10 Deaths Occurring Since May, 1965 
Age at Kidney Function Just Before Death Time 
First Patient Retransplantation 
LD No. Transplant Survival BUN (mg%) Cr (mg%) Ccr (ml/min) Cause of Death Before Death 
15 23 8 yr., 11 mo. 70 2.5 30 Pancrea ti tis No 
Chronic aggressive hepatitis 
18 39 2 yr., 6 mo. 32 1.6 60 Myocardial infarction No 
27 20 2 yr., 9 mo. Failed Kidney Bronchopneumonia 1 Month 
30 40 4 yr., 3 mo. 25 1.6 15 Perforated sigmoid diverticulitis 2 Months 
36 43 1 yr., 11 mo. 50 1.5 30 Systemic CMV infection No 
Chronic aggressive hepatitis 
Sacral cellulitis 
40 21 8 yr., 2 mo. 60 1.4 40 G I bleeding 18 Months 
Chronic aggressive hepatitis 
Hepatic failure 
44 48 5 yr., 4 mo. Failed Kidney Suicide by refusing dialysis 2 1/2 Months 
45 35 3 yr., 1 mo. Failed Kidney Cardiac arrest while on dialysis No 
47 37 1 yr., 9 mo. 65 3.5 10 Aspergillus pneumonitis No 
Pneumocystis carinii 
Fatty infiltration of liver 
Systemic CMV infection 
48 34 7 yr., 3 mo. 60 3.0 15 Myocardial infarction No 
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TABLE 4. Data on Primary Homografts 
LD Azathioprine Prednisone 
No. Date Op Donor HL-A Match BUN Ccr (ml/min) BP mg/day mg/day 
1 11/24/62 Mother C t t t t t 
2 1/31/63 Sister A 19 70 120/80 100 0 
3 2/9/63 Brother A 11 133 110/70 150 0 
6 4/17/63 Brother D 12 90 115/90 200 10 
12 6/7/63 Brother B 20 68 140/90 100 15 
13 7/3/63 Mother D 17 70 106/50 87.5 7.5 
14 7/5/63 Brother B 12 120 130/90 150 0 
15 7/8/63 Brother B t t t t t 
17 7/19/63 Mother B 10 64 130/95 100 2.5 
18 7/24/63 Sister D t t t t t 
22 8/12/63 Mother B 25 80 115/80 137.5 5 
25 8/21/63 Brother C 18 80 110/70 50 10 
27 9/3/63 Unrelated D t t t t t 
30 9/30/63 Unrelated D t t t t t 
33 10/7/63 Mother B 14 85 130/80 125 0 
34 10/11/63 Mother C 13 60 110/75 50 0 
36 10/14/63 Unrelated B t t t t t 
37 10/18/63 Mother C 24 80 120/80 75 15 
39 11/13/63 Mother C 23 65 115/80 125 10 
40 11/16/63 Mother A t t t t t 
41 11/23/63 Mother C t t t t t 
42 11/27/63 Father D 24 70 110/70 125 7.5 
44 12/7/63 Sister A t t t t t 
45 12/10/63 Sister C t t t t t 
47 1/4/64 Brother B t t t t t 
48 1/10/64 Sister A t t t t t 
49 3/3/64 Sister B 15 70 110/70 0 0 
50 1/25/64 Father C t t t t t 
51 2/10/64 Aunt E 17 68 90/75 125 10 
52 2/17/64 Father B 14 90 140/60 150 7.5 
53 2/22/64 Uncle C 26 57 90/60 100 5 
54 2/24/64 Unrelated C t t t t t 
55 2/26/64 Father C 30 40 120/80 150 15 
58 3/13/64 Sister A 16 98 120/80 125 10 
60 3/17/64 Cousin D 59 35 150/110 62 5 25 
63 3/27/64 Unrelated B 26 90 130/90 125 12.5 
1 = Subendothelial glomerular capillary basement membrane thickening. 
2 = Subepithelial glomerular capillary basement membrane thickening. 
3 = Increased cellularity of glomerular tufts. 
4 = Increased amount of mesangial matrix. 
5 = Tubular atrophy. 
6 = Interstitial fibrosis. 
7 = Mononuclear cell infiltration of the interstitium. 
8 = "Hyaline" in arteriolar walls. 
9 = Thickening of intima of interlobular arteries. 
o = No glomerular lesions compatible with glomerulonephritis 
NO = Impossible to be transmission of glomerulonephritis because original disease in no way immunological. 
NO = Very unlikely to be transmission because original disease chronic pyelonephritis. 
(NO) = Unlikely to be transmission, but possible because original disease glomerulonephritis. 
All 14 of those who were adults (18 or older) at the 
time of transplantation are employed, frequently in jobs 
for which they were specifically trained postoperatively. 
Twelve of the survivors were "pediatric" patients (ages 
3-17). The three-year-old who is now almost 14 is a 
healthy, but physically stunted school boy. The other 
11 have reached adulthood and are college students or 
job holders. Our patient who was a 21-year-old unskilled 
brain-damaged student is now a 32-year-old alcoholic 
day field worker. 
Three of the patients who were adolescents at the 
time of transplantation developed necrosis of one or 
both of the femoral heads during the early postoperative 
period. Two of the three learned to walk adequately 
despite this handicap. The third had bilateral total hip 
replacement performed successfully nine years post-
transplantation. 
Eleven of the 64 patients of the original series have 
had children after transplantation. Two of these parents 
who were female have had three children and the nine 
male parents have fathered 13 ,children. One of the 
offspring of a male patient (LD 63) had a meningomye-
locele which was surgically repaired. None of the pa-
tients who became parents during the post-transplanta-
tion period has died. 
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oj 36 Renal Recipienls* 
Time 
Glomerular Primary Time 
Time Overall Nephritis Graft Patient 
Biopsy Glomerular Pathologic Original 111 Function Survival 
(YIonths) 2 3 4 Index 5 6 7 8 9 Index Diagnosis Transplant (Months) (Years) 
2+ 2 0 2 1 1. 25 2 1 2 1 2 1.44 CPGN (T) 65 11.4t 
24 0 0 0 0 0 0 0 0 0 0 0 CPGN 0 135 11 .3 
24 2 0 0 0 .5 0 1 0 0 0 .33 CLGN (NO) 134 11.2 
23 0 0 0 0 0 0 1 0 0 0 .11 CPG?\' 0 132 11 
22 0 0 0 0 0 2 2 1 1 3 1.0 RPG'J 0 131 10.9 
21 0 0 0 0 0 1 1 3 1 1 .78 CPG'J 0 130 10.8 
21 0 0 0 0 0 1 1 1 2 0 .55 Unknown 0 130 10.8 
21 1 0 0 0 .25 1 1 1 1 1 .67 CPGN (NO) 107 89t 
26 0 0 0 0 0 1 1 1 0 1 .44 CPYN 0 129 10.7 
26 2 0 0 2 1.0 2 2 2 2 2 .56 CMGN (KO) 30 2.St 
25 1 0 0 0 .25 1 2 1 0 2 .78 POLY NO 129 10.7 
24 0 0 0 0 0 0 1 1 0 0 .22 Unknown 0 128 10.7 
24 3 0 2 2 1.75 1 1 1 1 3 1. 56 CPGN (T) 31 2.8t 
21- 3 0 1 2 1.5 3 3 3 3 3 2.33 CMGN T 48 4.3t 
13 0 0 0 0 0 0 0 0 0 0 0 CPGN 0 127 10.6 
23 0 0 0 0 0 0 1 1 0 1 .33 CPGN 0 127 10.6 
22 2 0 0 0 .5 3 3 1 2 3 1.56 CPYN NO 23 1.9t 
22 0 0 0 0 0 1 1 1 0 1 .44 CPGN 0 126 10.5 
22 0 0 0 0 0 1 1 1 0 0 .33 CPGN 0 126 10.5 
22 2 0 3 3 2.0 1 1 2 3 3 2.0 CLGN (T) 77 82t 
22 .3 0 2 1 1.5 1 1 1 1 2 .33 CPGN (T) 73 10 At 
22 0 0 0 0 0 1 1 1 0 1 .44 Unknown 0 125 10.4 
60 4 4 2 4 3.5 4 ,1 2 4 2 3. 11 CPGN T 60 53t 
25 .3 0 1 1 1. 25 t 1 1 2 2 1.33 CPG?\' (T) 34 .3 .It 
22 2 0 0 1 .75 2 3 2 0 4 1. 56 CI'GX (NO) 20 1.8t 
24 2 0 () 2 1.0" 1 1 0 0 1 .78 CPGN (NO) 87 7.3t 
22 1 () 0 1 .5 1 1 0 0 () .44 CLGN (NO) 122 10.2 
24 1 () () 0 .25 1 1 1 () 2 .67 CPGN (NO) 69 10.3t 
23 2 () () 1 .75 1 1 1 .3 1 1. 11 CPGN (NO) 123 10.2 
23 1 0 0 0 .25 0 1 0 0 1 0.33 CPGN (NO) 122 10.2 
23 1 0 0 0 7-. _.) 0 1 1 1 1 .55 CPGN (NO) 122 10.2 
22 4 2 3 3 2. 75 3 .3 3 2 3 2 89 CPGN T 27 10.2t 
23 1 0 0 1 .5 1 1 1 2 3 1. 11 CPGN (NO) 122 10.2 
21 () 0 0 0 0 0 () 0 0 0 () CPGN 0 122 10.2 
22 2 0 0 3 1. 25 2 2 2 0 0 1 .22 CPGN (0."0) 121 10.1 
22 4 0 2 4 2.5 1 2 2 1 1 .89 CPGN (T) 121 10.1 
----
(T) = Probably transmission of glomerulonephritis. 
T = Almost certainly transmission of glomerulonephritis. 
CLGN = Mesangiocapillary chronic lobular glomerulonephritis 
CMGN = Chronic membranous glomerulonephritis 
CPGN = Chronic proliferative glomerulonephritis 
CI'Y'J = Chronic pyelonephritis 
POLY = Polycystic disease 
RPGN = Proliferative glomerulonephritis with crescents 
* Patients \yere alive when reported in 1965 24 and 26 of them survive 9 years later in 1974. Additional data on the patients who required 
retransl'lantation are in Table 1. 
t Alive following: retranspiantalions. 
t Dead. 
Histopathologic Correlations 
The h\O-year biopsies were included as part of a 
report made to the American Surgical Association in 
1970.26 These analyses were accepted as the histo-
pathologic basis for the following correlations. 
Overall Pathologic Index. When the nine light micro-
scopic categories at two years were averagcd (Table 4) 
it was found that kidneys having a mean index less 
than 1.33 had a 87.5% chance of functioning for the 
enSiling eight to ninc-and-one-half years (21 of 24). 
Two of the three patients whose kidneys no longer 
function d('spite a score less than 1.33 died of pancrea-
titis after 107 months (LD 15) and myocardial infarc-
tion after 87 mon ths (LD 48). These kidneys had not 
failed although they were subnormal in their perform-
ance (Table 3). The third patient (LD 50) had a score 
of 0.50 at two years with homograft failure after five-
and-one-half years. She underwent retransplantation. A 
pattern of sporadic discontinuance of immunosuppres-
sion for long intervals was latcr uncovered. 
Ten of the 11 two-year biopsies with an overall pa-
thologic index of 1.33 or greater wcre eventually lost 
( 91%), after a total functional interval of 23 to 77 
(mean 43) months (Table 4). In one case (LD 18), in 
which the index scorc was 1.56, the patient had a 
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TARLE 5. HL-A Matches of 36 Kidneys Which Were Functioning 
in May, 1965 
Primary Kidney 
Match* Still Functioning 
At 3 (50%) 
B 8 (73%) 
c 6 (55%) 
D-E 5 (63%) 
Primary 
Kidney 
Failed 
2 
2 
5 
2 
Death 
Without Failure 
of Primary Kidney 
1 
1 
o 
1 
* Five of the 36 kidneys functioning in May, 1965, were unrelated. 
The only one still functioning had a B match. One of the 4 unrelated 
kidneys which failed also had a B match, one was a C and 2 were 
D-E. 
t Five of the 6 A matches were siblings and were thought to repre-
sent double haplotype HL-A identity of the donor and recipient. 
functioning graft but died of a myocardial infarction 
30 months post-transplantation. Nine other grafts either 
failed and were removed or were functionless in place 
at the time of the recipients' death. Homograft loss 
was avoided only in Patient LD 63 who had a two year 
overall pathologic index of 1.89. Now after ten years 
and two months, the BUN is 26 mg% and the creatinine 
clearance is 90 mljmin. During all this time he has 
not had Significant proteinuria. Reassessment of the 
two-year biopsy did not show any features which ex-
plained the atypical subsequent behavior of this dam-
aged graft. It is of interest that this patient was studied 
in 1966 by Dr. Fritz Bach of Madison, Wisconsin who 
performed a mixed lymphocyte culture examination 
with the peripheral blood of the recipient and his donor. 
Although a clear donor-recipient histoincompatibility 
was detectable by serologic typing, the recipient lym-
phocytes no longer underwent blast transformation when 
exposed to killed donor white cells, although they 
reacted vigorously to third party lymphocytes. The 
findings were interpreted as indicating speCific acquired 
immunologic tolerance.1 
Homograft Glomerulonephritis. When the two-year 
biopsies were reviewed in 1970,26 a diagnosis of definite 
glomerulonephritis in the homograft was made if, by 
light microscopy, over 50% of the glomeruli showed 
one or more of the following features: 1) focal or diffuse 
hypercellularity of the tufts and 2) focal or generalized 
thickening of the capillary basement membranes. These 
two basic pathologic changes might, or might not, be 
accompanied by epithelial cell crescents, by a focal or 
generalized increase in the amount of mesangial matrix, 
and by the presence of deposits of immunoglobulins 
and complement on the glomerular capillary wall. 
Glomerulonephritis was considered a possibility if the 
glomeruli appeared normal on light microscopy but: 
1) electronmicroscopy revealed an excess of predomi-
nantly non-cellular material on either aspect of the 
. glomerular capillary basement membranes; the material 
could be of any degree of electron density; and/or 2) 
immunofluorescence demonstrated deposits of immuno-
globulins and complement on the glomerular capillary 
walls. The deposits could be in a granular, linear or 
mixed pattern. 
Using these criteria, 22 of the 35 renal homografts 
biopsied at two years were diagnosed as haVing glo-
merulonephritis, for an incidence of 63%. All 13 kidneys 
without glomerular lesions at two years are functioning 
today, whereas only nine of the 22 kidneys with such 
lesions continue to support life. 
The homograft attrition was even greater when the 
glomerular lesion in the two year biopsies were thought 
to either certainly or probahly represent transmission 
of the patient's original disease, as judged by comparison 
with the histopathology of the destroyed native kid-
neys. Seven (LD 1, 27, 30, 40, 41, 45 and 54) of the 
eight homografts carrying the firm two year diagnosis 
of "transmission glomerulonephritis" failed 27-77 months 
post-transplantation (average 51 months). An eighth 
TABLE 6. Features of Cancers in Original Colorado Transplant Recipients 
Followup 
Age at Time Time of After Initial 
of Onset After Diagnosis of 
Transplant Transplant Tumor 
LD No. (Years) (Month) Type of Tumor Treatment Outcome (Month) 
6 23 75 Basal cell carcinoma Excision No recurrence 58 
of face 
30 40 32 Squamons cell carcinoma Wide excision No recurrence; died of 20 
of skin of ear perforated diverticulitis 
48 34 74 Squamous cell carci- M ul tiple excisions Died of myocardial infarction 14 
nomas of forearms, 
right arm, and scalp 
55 21 87 Squamous cell carci- Excision and skin Eight months later had 35 
noma of face; pre- graft resection of pre-auricular 
auricular lymph node lymph node metastasis and 
parotid gland 
60 21 78 Multiple squamous cell Multiple excisions Recurrences; currently being 43 
carcinomas both upper treated with topical 5FU 
extremities, face, right 
knee, lower lip 
63 35 66 Sq uamous cell carcinoma Excision No recurrence 55 
of lower lip 
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kidney which was not biopsied at two years failed at 
five years and was found also to have transmission 
glomerulonephritis (LD 44). The only kidney with the 
stigmata of transmission glomerulonephritis at two years 
which still functions after ten years is in Patient LD 63. 
The devastating prognostic impact of two-year glo-
merular lesions upon late graft survival could be seen 
from the glomerular index which was the average of 
histopathologic Categories 1-4. If the index was less 
than 1.00 at two years, renal function at one decade 
was achieved in 83% (20 of 24). With a glomerular 
index of ::0: 1.00, the decade success rate was only 18% 
( two of eleven). 
Next to the glomerular abnormalities, the presence 
or absence of arteriolar and arterial lesions provided 
the best prognostic insight (Table 4). Cellular invasion, 
tubular atrophy and interstitial fibrosis were progres-
sively less reliable. However, all categories of lesions 
scored higher in the kidneys which eventually failed. 
Discussion 
In 1962 and 1963, three American9,16,25 and one Euro-
pean~9 centers were acquiring experience with the drug 
combination of azathioprine and prednisone for the 
prevention or reversal of renal graft rejection. The prog-
ress and the avalanche of observations that followed 
had amplified significance because of parallel advances 
in renal dialysis technology by which preoperative re-
cipients could be resuscitated and held in preparation 
for transplantation or else maintained postoperatively 
in the event of homograft failure. 
The results from the early days of azathioprine-
prednisone therapy were unsatisfactory by present day 
standards, mainly because of the very heavy death rate 
during the first postoperative year which was particu-
larly devastating in the nonrelated cases. The marked 
reduction in the early mortality and the means by 
which this has been achieved have been recently re-
viewed.27 The important collateral issue of the long-
term outlook of the patient who has passed through 
a successful early course is a question which the present 
communication partly answers. 
In 1965, when these cases were brought to the 
attention of the American Surgical Association, the 
summary statement was made that " ... for the present 
it would seem most reasonable to regard homotrans-
plantation as an effective, but incompletely character-
ized, form of palliative therapy."24 Now, nine years 
later, with 26 (72%) of the 1965 survivors still alive 
and 22 bearing their original homografts, more optimism 
than ever seems justified about the lasting qualities 
of homo grafts if the donors are related. 
Using unrelated donors, late losses occur more fre-
quently. In our experience, improvement in patient 
survival with the use of unrelated organs under pres-
ently employed immunosuppressive regimens, including 
those using ALG, will require acceptance of a much 
heavier rate of retransplantation than with consanguin-
eous donors.27 
The hypothetioal Achilles' heel of successful organ 
transplantation under chronic immunosuppression was 
once projected to be death from complications of im-
munologic invalidism. The fallacy of this fear has been 
demonstrated by the followups in the present report. 
The survivors have had remarkable long-term rehabili-
tation, both social and vocational, and most have had 
a very nearly unrestricted return to society. Except for 
hepatitis, infection has played no role in the deaths 
after three years. The increased incidence of de novo 
malignancies in the transplant population is acknowl-
edged to be a penalty for chronic immunosuppression 
and the consequent partial loss of immunologic compe-
tence,26 but the resulting neoplasms have usually been 
treatable by conventional means with the notable excep-
tion of mesenchymal malignanciesP 
The greatest risk to life that the transplant recipient 
faces is late slow deterioration of the homograft and 
cardiovascular and other complications of the recurrent 
uremia. The correlations in the present report have 
shown how the quality of the two year biopsy can 
predict the functional future of the homografts. In 
passing, it may be noted that with the possible excep-
tion of perfectly matched siblings, neither the biopsies 
nor the chronic clinical course correlate well with the 
HL-A match. 
In the past, the most prognostic ally serious stigmata 
to be found in chronic renal homo grafts have been 
thought to be arterial occlusive lesions.21 ,23 However, 
in the cases herein reported, glomerular abnormalities 
were even more discriminating than the vascular ones. A 
kidney with serious glomerular pathology at two years, 
had less than a 10% chance of being functional at a decade. 
The meaning of glomerular abnormalities in renal 
homografts has been the subject of much discussion 
but two principal mechanisms could contribute. In one 
instance, the autoimmune disease which destroyed the 
host kidneys could be recapitulated in the new kidneys, 
as has been particularly well documented in identical 
twins.4 On the other hand, the immunologic events of 
rejection can probably manifest as glomerulonephritis 
since glomerulonephritis has been seen after animal 
transplantation2o,3o or transplantation to humans whose 
original disease was not autoimmune in nature.7 ,19 The 
probable contribution of both kinds of damage to the 
loss of transplants has been emphasized by a number 
of authorities.2,5,6.1o,12,18,28 The prognostic reliability of 
glomerular pathology is probably as high as it is because 
it picks up both of the aforementioned main pathways 
of graft injury. With either recapitulation of the original 
disease or glomerulonephritis secondary to rejection, the 
immunologic injury could be produced by fixation of 
anti-GBM antibodies in the graft or more commonly, 
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lodgement of antigen-antibody complexcs in the graft. 
More precise conclusions about these mechanisms will 
require identification of the spccificity of both antigens 
and antibodies within grafts by elution and other 
immunologic teclmiqllcs. 
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interested in and, in fact, he published a paper on this in 1968; 
namely, how much can we decrease our ill1munosuppressive 
therapy in these long-term patients, and can we ever discontinue 
these drugs completely. 
After reading Dr. Starzl's paper, I never had the courage to 
drop immunosuppression completely, but seven of our patients did 
this by themselves and the results were disastrous. 
Some of these patients, fortunately, came to the foIlowup clinic 
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in time; they.had elevated creatinines and were restarted on im-
munosuppressive therapy. Their renal function improved, al-
though rarely to the pre-existing level; some of these patients 
lost their kidney. 
One of these' patients, transplanted by Sam Kuntz at Stanford, 
was a young woman, seven years postoperative, with a creatinine 
of 0.9 and taking 10 mg of Prednisone and 100 mg of hnuran. 
She became pregnant and her obstetrician suggested that she 
drop her immunosuppressive therapy, which she did without 
telling us.·She delivered a normal child, did well for six 
months, and then arrive(] at our hospital with a creatinine of 11. 
\Vc were never ablc to reversc the rejection. 
I think there are three points to be made from this. First, I do 
not believe we should drop immunosuppression, even for long 
standing patients, below a certain level; and in adult patients, we 
should not drop the Prednisone dose below 10 mg. 
Second, we must remember that even long-term patients should 
be followed for the rest of their lives. 
Lastly, we should emphasize to long-term survivors that the 
three or four little pills they take in the morning are still the 
difference between life and death. 
DR. BJellAHD E. WILSON: (Boston) I thought it would be of 
interest to the Association for me to provide a comparable series 
of patients for discussion of Dr. Starzl's valuable presentation. 
Dr. Tilne\' and I recentlv reviewed the results of renal transplants, 
exclusive '01' identical twins, performed at the Peter Bent Brigham 
Hospital in exactly the same time period, September 1, 1962 to 
March 31 1964. 
Forty such allografts were performed, 19 from living related 
donors, five from cadaver donors, and six from obligatory Ull-
related living donors of Matson type of kidney. None of the 
cadaver or obligatory unrelated ionor kidney recipients trans-
planted during that time period lived tlw one year maximum, 
although one patient, transplanted in April of 1962 from a cadaver 
donor lived for two years on his transplant. 
Of the living related donor recipients, therefore, 16 of 19 lived 
more than one year, or 84%; 8 of 19 lived more than five years, 
4O~; and 7 of 19 lived more than ten years, 37%. 
One patient who lived four years received three kidneys before 
he di('cl, two of those cadaveric. One patient now living over ten 
years received a second kidney from a cadave; aft~r fivc veal'S 
on his first kidnev. He, by the way, was a patient 1Il whom we 
had tried to stop' his prednisone; when we tried to restart it, we 
could never retrieve the rejecting kidney. 
No malignancies developed in any of these recipients. Another 
patient tbat I transplanted in Oslo in 1963 from his mother is still 
alive and \\'('11, never having had a rejection in these eleven years. 
I think it is interesting that, while a greater proportion of our 
patients lived more than one year than those that Dr. Starzl re-
ported, there has been a greater patient attrition at the 5- and 
1O-year period. With these small numbers, these variations from 
Dr. Starzl's series may not be significantly different, but I wonder 
wbether there was any selective process, on the basis of tissue 
typing, in choosing his donor-recipient pairs. 
We have never excluded any patients, and still don't, for tissue 
type, just for positive crossmatch. 
Du. JOHN SARKIS NAJARIAN (Minneapolis): Dr. Starzl stressed 
the durability of the transplant, and I think this is important. In 
our own experience, using our pediatric group as an example, of 
over 100 children during a ten-year period, we have found the 
same, or perhaps slightly better, degree of durability. 
For instance, an actuarial table of our related kidneys in chil-
dren reveals that we have 70% kidney survival at ten years, and 
practicallv no attrition between five and ten ~earsK In our. series 
of cadaveric kidney n'cipicnts 50% of the chIldren arc alive at 
ten years with functioning kidneys. 
The remarkable thing is that 80% of the 100 ehildren are still 
alive with first, seeond and third kidneys. None of the children are 
presently on dialysis. These data emphasize not only the durability 
of children, but also their ability to accept retransplantation so 
well. 
\Vhy are our results in children slightly better than those of an 
adult population? You will note from Dr. StarzI's slides that the 
parent group was his best group. The kidneys in our pediatric 
group were predominately from parent donors. 
Another factor contributing to the poorer results in our adult 
recipient population is that deaths that occur in chronic patients 
are usually from causes other than immunologic causes. These 
non-immunologic causes of death, such as m~DEFcardial infarction, 
are becoming more and more of a factor as time progresses. In 
small children, however, this is not a problem. 
I'm a bit perplexed by a couple of things, so I would like to 
ask two questions. First, in his typing data on the related donors 
his worst results were with the A-matched patients, those in which 
we would expect the best results. I wonder, when you look back 
on those patients, whether or not those patients were actually 
"overly immunosuppressed." In those early days we didn't really 
attempt to type them as we should have, and today if we trans-
plant an A-matched patient, we reduce our immunosuppression, 
as I'm sure you do. If we had done so in the past perhaps we 
would have salvaged more patients. 
If the same degree of immunosuppression is given to an A-
matched patient as is given to a D- or E-matched patient, the 
patient is "over immunosuppressed", and can succumb to steroid 
problems and infections. I wonder if this is the way Dr. Starzl 
would look at that particular data. 
The second question has to do with the glomerular lesion. It's 
intriguing to think about possible antigen-antibody viral glom-
erulonephritis, as Tom has mentioned. The lesion he showed was 
of membra no prolific disease. \Ve have shown that in children and 
adults this disease has about a .50-60% recurrence, and is quite 
characteristic in pathology. I'm wondering if those that Dr. Starzl 
saw had membranoprolific nephritis as their original disease? 
DR. TnoMAs C. MOORE (Torrance, California): \Vhen Dr. 
David Hume and I reviewed the Richmond transplant experience 
six years ago, we had the impression that a 2-3-year followup was 
needed to assess the results of the transplant effort. This appeared 
particularly true for the recipients of cadaveric donor kidneys. Ap-
proximately one-third of these recipients of cadaver donor kidneys 
in the Richmond experience at risk a minimum of three months 
had contracted hepatitis in the early posttransplant months, of 
which the majority died in liver failure between one and two 
years posttransplant. 
In rccent years my thoughts have changed somewhat concern-
ing the period of major, if not exclusive, bazard to renal transplant 
function from the immune response to the transplant. I now feel 
that the great bulk, if not all, of the transplant damage from the 
host immune response in recipients who take their immunosup-
pressive medication as directed comes in the first year posttrans-
plant. 
vVhen I visited Richmond four years ago to review the continu-
ing function of transplants I had reported with Dave IIume, I was 
dismayed to find that three of the ten functioning related living 
donor transplants, at risk at minimum of six years-a group which 
corrcsponds to Dr. StarzI's current decade plus followup-that 
three of these ten, 30%, had been lost in the prior 12-month 
period, all to nontransplant failure eauses. Two transplants were 
lost to rapidly fatal recipient malignant lymphomas, and one to 
recipient suicide. All three transplants had excellent function, 
with serum creatinines in the 0.8-1.1 range at the time of re-
cipif'nt death. 
( Slide) We have reeently studied the role of early transplant 
fllnction classes F, FAR, SF and NF, as shown OIl this slide, of 
Belzer machine preserved cadaveric kidneys on a long-term func-
tion, one to three years, of 146 kidneys transplanted at the USC 
County, UCLA Harbor, and UC Irvine transplant centers in our 
area. 
One-year transplant survival was .51% for the F class, pre-
sumahly nonpresensitized recipients; 29% for the FAR, the accele-
rated rejeetion class; 6.5% for the SF, or the slow-functioning class; 
and 40% for the NF, or nonfunctioning class. 
In the F functioning class, none of the five kidneys which 
survived for one year was lost after one year due to transplant 
rejection failure. There was one loss from death, a malignant 
perirectal lymphoma, at UC Irvine. 
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It is of particular interest to look at the non-F classes that may 
hI' rrpsumed to be sensitized in varying degrees to donor antigens 
in terms of humoral antibody. In this particular group we find 
that the long-term function of cadaveric kidneys, which have ex-
perienced some degree of presnmed immunological assault, is re-
markably good for those transplants which recover from this early 
assault. For example, one year plus transplant survival of 88% for 
the FAR group of kidneys; it is 79% for the SF group of kidneys; 
and it is 89% for the NF group of kidneys. The kidncy in the 
presumably presensitized recipient which is not, in a sense, killed 
by early immunologic injury from humoral antibody and "primed" 
lymphocytes appears to ae(luire the privilege of long-term func-
tional survival, possibly due to the development of enhancement. 
The F-c1ass transplants also offer a unique opportunity to study 
the clIect of other factors in long-term function in presumably 
non-presensitized recipients. HL-A matching appears to play no 
significant role in long-term function. 
Also for F recipients the use of splenectomy, carried out by 
Dr. Berne at USC County, appears to have a beneficial effect; 
88% one-vear survival of splenectomized recipients, as compared 
with only 44% for nonsplenectomized recipients, splenectomy hav-
ing been carried out for either excessive transfusion requirements 
or for leukopenia. 
I wish to ask Dr. Starzl three questions: 1) What per cent of 
the transplants lost after one year were due to rejection? 2) What 
was the role of early transplant fnnction, if this data is available, 
in long-term survival of patients in his long-term series? And 3) 
what is your current feeling concerning the value of splenectomy 
clinically in the renal transplant patient? 
PnoFFssoH MAumeE ROSSIE EWING (Melbourne, Australia): At 
the Royal Melbourne Hospital we have a modest experience in 
renal transplantation, only recently having passed the 200 mark. 
Of these patients, all of them save two or three have been 
cadaver grafts. Only a handful of them, thus far, has passed the 
ten-year mark, so my remarks are not really relevant to the title 
of this paper; but we are, in fact, deeply disturbed already by 
the premature development, in the young, of the kind of degenera-
tive cllanges in the skin with which we are very familiar in the 
eldcrly, after exposure over a lifetime to the sun. The incidence 
of skin cancer in the survivors after four years is 18%, and, of 
course, many of these patients have multiple skin cancers. 
Thus far-I think, with only one exception-these skin cancers 
have been contained by simple surgical excision. 
It's also a matter of interest that we have encountered a few 
patients, who have been put on long-term azothioprine for other 
causes, with skin cancer, but how these numbers relate to the 
total numher at risk, and against a backdrop of a really high 
incidence of skin cancer in our community, it's not very easy to 
determine the relevance of this experience. 
PnoFEssoll LAHS-EIUK GELIN (Goteborg, Sweden): I rise to re-
port the long-term results in our own series, (slide) which, how-
ever, only counts for the first eight years. And as seen, in the 
living donor series it's a 40% graft survival after eight years but 
only 18% cadaver grafts. 
( Slide) This shows the patient survival for the same period of 
time, 65% in the living donor series and 40% in the cadaveric donor 
series. 
( Slide) Our series is based on the principle that transplantation 
is the method of choice. \Ve have no mortality in dialysis in our 
department. Everything goes on transplantation, and as soon as 
a graft is failing, we perform rdransplantation and during a re-
trallSplant series we observed that in case we could do the retrans-
plant while the prior, primary graft still had marginal function, 
the graft survival was very much superior to the situation when 
there is an interval between transplantectomy and regrafting, and 
this is the series showing this. 
\Vhat is the mechanism behind this privileged time for retrans-
plantation? 
Dn. THO\lAS E. STAHZL (Closing discussion): It seems to me 
that Professor Gelin's remarks illustrate the imperfections of treat-
ment as it has heen carried out in the last ten or 12 years, and, 
I would think, should be a real admonition not to consider this 
field fully developed. ' 
It's my own conviction that some time in the next year or two 
there will be a very significant advance in immunosuppression, 
and possibly related to the kind of research work that is being 
carried out by Monaco and his associates in Boston, in which 
much more emphasis is heing placed on the possibility of tolerance 
induction. 
Professor Ewing's remarks could be used to make the same 
point as Professor Gelin's, because, obviously, the risk from 
the skin cancers-and we too have observed this-is clearly re-
lated to chronic immunosuppression. This matter may come up 
again in connection with Dr. Simmons' paper on the role of 
viruses in the oncogene tic mechanisms. 
Naturally, I want to thank myoId friend, John Najarian, and to 
try to answer his questions. Ours is a small series of A-matched 
sibling cases. We do believe there is an advantage of recciving 
an A-matched sibling kidney which did not, however, show up 
in our small early series but only later in our larger experience. 
I don't think that over-immunosuppression led to the loss of 
those grafts that were still functioning in 1965, because we had 
already pulled off the heavy immunosuppression that we were 
using. By then, the patients were a year to two years posttrans-
plantation, and by and large were in a pattern of light immuno-
suppression. 
The question about the type of glomerulonephritis is an im-
portant and perceptive one. I tried to answer it in the manuscript, 
but it would take too long, and I'm not expert enough in pathol-
ogy to warrant going into it at this time. 
Dr. Wilson, you asked two questions. One concerned the type 
of sclection. Like you, our selection was fortuitous in those years, 
1962 to 1964, since there were no good or even acceptable donor-
recipient typing techniques at that time. In fact, we did not even 
hother to follow the rules of red blood type matching, which have 
become recognized to be of such paramount importance since 
then. Thus, good matching was not a factor. 
Dr. Wilson, with his customary modesty, focused only on this 
period of time that I did, and failed to mention that the longest 
homotransplant survival in the world is a Boston recipient of a 
fraternal twin kidney treated in 1958. As I understand it, thal 
patient is still alive. 
Dr. Belzer raised the question about whether kidneys can 
be permanently accepted in the human being, as they can in 
animals. In our manuscript we relate an expel'ience with two 
patients who stopped their immunosuppression-probably, in one 
case, in 1971. The second patient definitely stopped his im-
munosuppression about 15 months ago. Neither recipient has 
suffered any ill effects. But we certainly llave our fingers crossed, 
because the story that Dr. Belzer has told has been repeated now 
on many occasions, and usually with dire consequences. 
Dr. Moore asked three specific questions. One concerned our 
opinions about the stability of grafts after one year, and we agree 
with him, in general, that as the life survival curves would in-
dicate, there is Telative stability. Second, we believe the greatest 
risk the transplant recipient must face is not cancer or infection, 
but slow failure of his homograft with physical deterioration 
before retransplantation or return to dialysis. 
The question about earl\' function versus late results is one I 
cannot answer on the basis of these data, because, as you may 
remember, almost all of these kidneys functioned superbly from 
the beginning. Therefore, it would be difficult to make the kind 
of correlations that you suggest. 
Splenectomy, as far as I'm concerned, is an unproven issue in 
the human, and probably is not provable on the basis of clinical 
investigation. If you believe in basic biology, there is plenty of 
evidence that splenectomy is a biologic immunosuppressive 
maneuver, but just what effect it has on transplant survival, I 
think is unanlyzable. 
May I make one final comment before closing? This is the first 
American Surgical mecting that I have ever lwen to that was not 
graced by the presence of Dave Hume. It is strange to give a 
paper on Dave's favorite subject, realizing that his smiling face 
and swashbuckling emanations are not today, or ever again, going 
to be working their way to the podium-usually down that aisle 
(indicating )-to set up a lively but always good-naturcd duel. 
I, for one, have no intention of forgetting our good friend 
simply because he is not with us today. Thank you. 
